Please assess the completion status of the following clinical trial:

Trial Title: Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females between 4 years to 55 years of age,~2. Thermal burns caused by fire/flame, scalds or contact,~3. Deep partial thickness (mixed deep dermal) and/or full thickness (3°) burn wounds ≥ 5% and ≤ 30% Total Body Surface Area (TBSA); all these wounds must receive study treatment,~4. At least one wound of ≥ 2% TBSA deep partial thickness and/or full thickness burn,~5. Total burn wounds ≤ 30% TBSA,~6. Signed written informed consent.~Exclusion Criteria:~1. Deep partial thickness and/or full thickness facial burn wounds, \> 0.5% TBSA; study treatment of facial burns is not allowed,~2. Study treatment of perineal and/or genital burns (A patient with these wounds may be enrolled but the wounds may not be designated as target wounds),~3. Circumferential anterior/posterior trunk full thickness fire/flame burns, \> 15% TBSA, (Circumferential is defined as encircling ≥ 80% of the trunk circumference.)~4. Pre-enrollment escharotomy,~5. Heavily contaminated burns or pre-existing infections,~6. Signs that may indicate smoke inhalation,~7. General condition of patient would contraindicate surgery,~8. Pregnant women (positive pregnancy test) or nursing mothers,~9. Poorly controlled diabetes mellitus (HbA1c\>9%),~10. Cardio-pulmonary disease (MI within 4 weeks prior to injury, pulmonary hypertension, COPD or pre-existing oxygen-dependent pulmonary diseases),~11. Pre-existing diseases which interfere with circulation (PVD, edema, lymphedema, surgery to the regional lymph nodes, obesity, varicose veins),~12. Immediate life threatening conditions (such as immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, cardiovascular, liver or neoplastic disease),

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- DGD (Type: EXPERIMENTAL): None
- SOC (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).